BioCentury
ARTICLE | Emerging Company Profile

Tallac: linking antibodies to DNA-triggered innate immunity

Emerging Company Profile: Tallac launches with $62M A round, pipeline of antibody-TLR9 agonist conjugates

December 9, 2020 1:24 AM UTC

Tallac debuted last week with a $62 million series A round to advance a pipeline of systemically delivered antibody conjugates designed to trigger innate immunity against cancer. 

The tranched round included venBio Partners, Morningside Venture, Lightstone Ventures, Matrix Partners China and MRL Ventures Fund...

BCIQ Target Profiles

Toll-like receptor 9 (TLR9)